Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
AbCellera Q2 2026 Earnings Call - TCE Platform Deals Inject $110M Upfront Cash and Validate Multi-Specific Pipeline
AbCellera is shedding its cash-burning discovery label and stepping into a de-risked clinical-stage operator. Enrollment for ABCL635 in menopausal hot flashes wrapped early, and management is tracking...
- ABCL635 Phase II enrollment for moderate to severe menopausal hot flashes finished ahead of schedule, with top-line data expected imminently.
- Management targets a 20 percent placebo-adjusted reduction in hot flash frequency and a minimum of two daily hot flash reductions as clinical success thresholds.
- ABCL635 aims to differentiate from approved small molecules by eliminating routine liver monitoring and avoiding NK1R-mediated somnolence through strict NK3R targeting.
- +9 more takeaways
Universal Technical Institute Q3 FY2026 Earnings Call - Guidance Trimmed on High School Conversion Miss, Skilled Trades Momentum and Long-Term Targets Hold
UTI delivered a clean third quarter with revenue climbing 7% to $219 million and new student starts surging 11%, yet management lowered full-year guidance to reflect a Q4 high school enrollment shortf...
- Third-quarter revenue rose 7% to $219 million, with new student starts jumping 11% year-over-year, driven by a 23% surge in the UTI division.
- Reported adjusted EBITDA came in at $18.2 million, weighed down by $9 million in strategic growth investments, while baseline adjusted EBITDA held at $27.2 million.
- Full-year FY2026 revenue guidance was lowered to a $893 million to $900 million range, with reported adjusted EBITDA trimmed to $100 million to $103 million.
- +8 more takeaways
Velocity Financial Q2 2026 Earnings Call - Portfolio Surges Past $7 Billion as Credit Tightens and Origination Volumes Accelerate
Velocity Financial’s second quarter of 2026 reads like a playbook for disciplined growth. The portfolio crossed $7 billion in unpaid principal balance, driven by steady demand across commercial and re...
- Total loan portfolio reached $7 billion in unpaid principal balance, marking a 19 percent year-over-year increase.
- Second quarter production hit $672.6 million, with unit volume up 3.3 percent year over year despite a slight dollar decline driven by smaller average loan sizes.
- Portfolio net interest margin came in at 3.66 percent, comfortably above the company’s 3.5 percent target.
- +9 more takeaways
"Sunrun" Q2 2026 Earnings Call - Direct Sales Pivot Trims 2026 Guidance While Storage and Grid Monetization Build the Next Growth Engine
Sunrun is deliberately compressing its 2026 volume to force a structural shift toward a direct sales model that promises higher margins, better asset quality, and tighter customer control. The tradeof...
- Sunrun is engineering a deliberate volume contraction to force a pivot to direct sales, cutting affiliate channel volume over 60 percent year-over-year while pushing direct to exceed 85 percent of total origination.
- Storage attachment hit a record 74 percent in Q2, driving over 15,500 battery installations and cementing 4.6 gigawatt hours of residential capacity as the nation’s largest distributed power fleet.
- Full-year guidance was trimmed across the board, with cash generation lowered to $200 million–$375 million and subscriber value cut to $4.6 billion–$4.9 billion, reflecting a slower direct ramp, collapsed affiliate volume, and higher capital costs.
- +7 more takeaways
Traeger Q2 2026 Earnings Call - Revenue Lowered, EBITDA Held Firm as Company Pivots to Accessible Pricing and Lowe's Expansion
Traeger delivered a mixed second quarter, with revenue contracting 17% to $120 million as lower average selling prices and persistent softness in the MEATER business weighed on top-line results. The c...
- Q2 revenue fell 17% to $120 million, driven by a 17% drop in grill sales and a 26% decline in accessories as MEATER promotional performance lagged expectations.
- Full-year 2026 revenue guidance was lowered to $435 million to $465 million, reflecting greater near-term channel friction and a wider range to account for timing variability.
- Adjusted EBITDA guidance remains intact at $57 million to $67 million, with Q2 results coming in at $17 million, up from $14 million a year ago.
- +7 more takeaways
"PacBio" Q2 2026 Earnings Call - SPRQ-Nx Adoption and Clinical Validation Outpace Near-Term Margin Pressures and Guidance Cut
PacBio’s second quarter of 2026 tells a story of technology winning the argument but economics demanding patience. CEO Mark Van Oene takes the helm as Christian Henry steps aside, inheriting a company...
- Leadership transition: Mark Van Oene assumes CEO duties as Christian Henry steps down, remaining on the board as a strategic advisor.
- Q2 revenue flat at $39 million year over year, with consumables growth offsetting a 9 percent decline in instrument sales.
- Full commercial rollout of SPRQ-Nx chemistry reduces cost per 20x HiFi genome to $345 and enables three uses per SMRT cell.
- +9 more takeaways
Evolus Q2 2026 Earnings Call - Raises Full-Year Guidance on Portfolio Momentum and Third Straight Quarter of Positive Adjusted EBITDA
Evolus is no longer pitching a single neurotoxin. The company is systematically building a three-vertical injectable platform, and the second quarter proved the strategy is translating into hard numbe...
- Q2 global net revenue surged 21% year-over-year to $84.1 million, with neurotoxin sales crossing $75.2 million.
- Management raised full-year 2026 revenue guidance to $330 million–$337 million and adjusted gross profit margin to 67.0%–67.5%.
- Adjusted EBITDA turned positive for the third consecutive quarter, reaching $4.7 million in Q2 and improving $12.6 million year-over-year.
- +7 more takeaways
Power Integrations Q2 2026 Earnings Call - High-Voltage GaN Roadmap and Margin Expansion Fuel Strategic Pivot to Data Centers and Energy Infrastructure
Power Integrations delivered a quarter defined by disciplined execution and a clear pivot toward high-voltage power semiconductor demand. Revenue climbed 10% sequentially to $119 million, while non-GA...
- Q2 revenue reached $119 million, marking a 10% sequential increase and 3% year-over-year growth, with expansion across all four end markets.
- Non-GAAP operating margin expanded over five percentage points to 17.1%, driven by a 160 basis point sequential jump in gross margin to 55.1% and disciplined expense management.
- Free cash flow hit $18 million, while channel inventory normalized to 7.3 weeks, landing squarely within the company’s 7-to-8-week target range.
- +8 more takeaways
"ADMA Biologics" Q2 2026 Earnings Call - ASCENIV Utilization Accelerates as Margins Expand and Full-Year Guidance Reiterated
ADMA Biologics delivered a quarter defined by structural leverage rather than headline volume growth. ASCENIV revenue jumped 24 percent to $102.9 million, lifting total revenue to $124.4 million and e...
- Total Q2 2026 revenue reached $124.4 million, up 2 percent year-over-year, primarily driven by ASCENIV growth.
- ASCENIV revenue surged 24 percent to $102.9 million, with June recording the strongest sequential end-user utilization growth since the first half of 2024.
- Gross margin expanded to 69 percent from 55 percent in the prior year period, reflecting favorable product mix shifts and manufacturing efficiency gains.
- +9 more takeaways
"Consumer Portfolio Services" Q2 2026 Earnings Call - Originations Surge 40% While Credit Discipline Holds Firm
Consumer Portfolio Services finally broke through its growth ceiling. Originations jumped 40% quarter over quarter to $758 million, powered by a 60% expansion in the sales force and an 84% surge in ac...
- Originations surged 40% sequentially to $758 million in Q2, marking a structural inflection point after a year of missed growth targets.
- Underwriting standards held firm: approval rates remained at 51% and debt-to-income ratios stayed flat despite rapid volume expansion.
- Credit quality improved sequentially, with 30-day delinquencies falling to 12.16% and net charge-offs dropping to 7.28% year-over-year.
- +8 more takeaways